GATA1 Activates HSD17B6 to Improve Cisplatin Efficiency in Lung Adenocarcinoma
Author Information
Author(s): Shao Xingxing, Hou Hailang, Chen Huijie, Xia Wan, Geng Xinpu, Wang Jindao
Primary Institution: Pulmonary and Critical Care Medicine, Huaian Hospital of Huaian City, Huaian Cancer Hospital, China
Hypothesis
Can GATA1 activation of HSD17B6 reduce cisplatin resistance in lung adenocarcinoma?
Conclusion
GATA1 activation of HSD17B6 inhibits cisplatin resistance in lung adenocarcinoma through DNA damage.
Supporting Evidence
- HSD17B6 was found to be lowly expressed in lung adenocarcinoma tissues and cells.
- Overexpression of HSD17B6 suppressed malignant phenotypes and cisplatin resistance in lung adenocarcinoma cells.
- GATA1 was identified as an upstream regulator of HSD17B6.
- Knockdown of GATA1 reduced the effectiveness of HSD17B6 in combating cisplatin resistance.
Takeaway
This study found that a protein called GATA1 helps another protein, HSD17B6, fight against a type of lung cancer by making the cancer cells more sensitive to a common treatment drug.
Methodology
The study used mRNA expression data, qRT-PCR, Western blot, chromatin immunoprecipitation, and cell viability assays to analyze the effects of HSD17B6 and GATA1 on cisplatin resistance.
Limitations
The study's findings need validation through clinical or animal experiments, and the specific molecular mechanisms between GATA1 and HSD17B6 were not fully explored.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website